Skip to main content

Table 3 Druggability case study. The protein coding change for variants are shown separated by a colon after the gene symbol. Databases listing the drug-gene interaction are abbreviated (T=TEND, M = My Cancer Genome)

From: CVE: an R package for interactive variant prioritisation in precision oncology

Variant Patient id dbNSFP score COSMIC Drug Database
EPHA2:p.S790F 26, 52 1.768360   tyrosine kinase inhibitor T
EPHA2:p.E607K 48, 87 1.737764   tyrosine kinase inhibitor T
GART:p.S635F 50, 56 0   folate antimetabolite T
KDR:p.S1100F 16, 45, 75 2.679266   tyrosine kinase inhibitor T & M
KIT:p.K642E 3, 27, 31, 70 2.454228 yes tyrosine kinase inhibitor T & M
KIT:p.V559A 25, 38 2.650527 yes tyrosine kinase inhibitor T & M
LHCGR:p.E206K 44, 45 0.77191 yes GnRH agonist T
MS4A1:p.G115E 52, 79 0   anti-CD20 antibody T & M
MTOR:p.A1105T 65, 66 0.8908875 yes mTOR inhibitor T & M
PDCD1:p.E211K 34, 51 0   anti-PD1 antibody M
PIK3C2G:p.E1231K 23, 48 0   PI3K inhibitor M
PRKCB:p.R361Q 44, 50 0.959385   protein kinase C inhibitor M
ROS1:p.P1539S 20, 26 0   tyrosine kinase inhibitor M